ROLKE JAMES (Chief Scientific Officer) received a stock award from LA JOLLA PHARMACEUTICAL CO
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 6/2/2020ACC: 0000920465-20-000081
Officer· Chief Scientific Officer
Since Aug 2018
+410.00
Net shares
Net buyer
$822.05
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
410.00 acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+205.00
Price / share
$4.01
Trade value
$822.05
% of position
0.3%
5/29/2020
81.57K→81.77K
Total
Net shares
+205.00
Net value
$822.05
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/29/2020 | A · Award | +205.00 | $4.01 | $822.05 | 0.3% | 81.57K | 81.77K |
| Total | +205.00 | $822.05 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
205.00 shares
Shares
+205.00
Strike price
4.72
Held after
205.00
Exercisable
—
5/29/2020
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock205.00 shares | 5/29/2020 | A · Award | +205.00 | 4.72 | — | 205.00 |